Pangaea Oncology, S.A. (BME:PANG)
Spain flag Spain · Delayed Price · Currency is EUR
1.700
0.00 (0.00%)
At close: Dec 4, 2025

Pangaea Oncology Company Description

Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries.

It offers molecular diagnostics, such as mutation analysis in tissue and liquid biopsy, gene amplification and translocation testing, immunohistochemistry and fluorescence in-situ hybridization, and gene expression profiling; clinical trials; in vitro drug profiling, including MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx platform, which performs companion diagnostic platform validation.

The company also provides biomarker discovery to improve treatment through identification of novel theranostic biomarkers.

Pangaea Oncology, S.A. was incorporated in 2006 and is based in Barcelona, Spain.

Pangaea Oncology, S.A.
Country Spain
Founded 2006
Industry Diagnostics & Research
Sector Healthcare
Employees 149
CEO Javier Rivela-Rodriguez

Contact Details

Address:
Sabino Arana, 5-19
Barcelona, 08028
Spain
Phone 34 93 409 79 81
Website panoncology.com

Stock Details

Ticker Symbol PANG
Exchange Madrid Stock Exchange
Fiscal Year January - December
Reporting Currency EUR
ISIN Number ES0105221008
SIC Code 2836

Key Executives

Name Position
Javier Rivela-Rodriguez C.F.A., M.B.A. Co-Founder, Chief Executive Officer and Director
Dr. Rafael Rosell Costa M.D., Ph.D. Chief Scientific Officer, Director, President and Member of Scientific Committee
Alejandro Garcia Moncayo M.B.A. Executive Director of Corporate and Chief Financial Officer
Carmen Albiol Head of Operations for IOR
Dr. Miguel Angel Molina B.Sc., Ph.D. Executive Director of Research and Development and Member of Scientific Committee
Alejandro Martinez M.D. Chief Medical Officer and Medical Director at IOR (Hospital Universitari Dexeus)
Cristina Masferrer EMBA Chief Business Officer